Home > Insider Trading > Filing (0001140361-16-060930)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1636282	Aeglea Biotherapeutics Inc.	AGLE	Pharmaceutical Preparations (2834)	V8

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1114448	Ag Novartis	Lichtstrasse 35 Basel V8 CH 4056		No	No	Yes	No
1297709	Ltd Bioventures Novartis	131 Front Street Hamilton Hm12 D0 0000000000		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-04-12	2,010,924	$0.00	2,010,924	No	4	C	Direct
Common Stock	Acquisiton	2016-04-12	300,000	$10.00	2,310,924	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2016-04-12	890,476	$0.00	890,476	$0.00
Common Stock	Series B Preferred Stock	Disposition	2016-04-12	1,120,448	$0.00	1,120,448	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Footnotes

In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated.
These securities are held directly by Novartis Bioventures Ltd. ("Novartis Bioventures"). Novartis Bioventures is a corporation organized under the laws of Bermuda and is an indirect wholly-owned subsidiary of Novartis AG. Novartis AG is a corporation organized under the laws of Switzerland and is the publicly owned parent of Novartis Bioventures Ltd.